Skip to main content

Academics

Press Release: 33 U.S. Clinical Studies Show Marijuana's Medical Use, New Journal Article Says

FOR IMMEDIATE RELEASE   
SEPTEMBER 14, 2009

33 U.S. Clinical Studies Show Marijuana's Medical Use, Journal of Opioid Management Article Says
Contrary to Opponents' Claims, Controlled Studies Have Repeatedly Demonstrated Safety, Efficacy


CONTACT: Bruce Mirken, MPP director of communications ............... 415-585-6404 or 202-215-4205


SEATTLE, WASHINGTON -- In a landmark article in the Journal of Opioid Management, University of Washington researcher Sunil Aggarwal and colleagues document 33 U.S. controlled clinical trials published from 1971 to 2009 confirming that marijuana is a safe, effective medicine for specific medical conditions.    


     Under federal law, marijuana is classified as a Schedule I drug, defining it as having high potential for abuse, unsafe for use even under medical supervision, and lacking currently accepted medical uses in the U.S. "In fact," Aggarwal and colleagues write, "nearly all of the 33 published controlled clinical trials conducted in the United States have shown significant and measurable benefits in subjects receiving the treatment."  Additionally, the paper documents the growing acceptance of the therapeutic use of marijuana among organized medicine groups and estimates that "in 2008, approximately 7,000 American physicians have made such authorizations for a total of approximately 400,000 patients."


     Regarding abuse and safety issues, Aggarwal et al. write that withdrawal symptoms -- a classic symptom of drug dependence -- are notably absent from the published trials, while "the vast majority of reported adverse events were not serious ... It is clear that as an analgesic, cannabis is extremely safe with minimal toxicity."


     Unfortunately, the article continues, ignorance regarding marijuana remains widespread in the medical community. "There remains a near complete absence of education about cannabinoid medicine in any level of medical training," Aggarwal writes.


     "This is arguably the most thorough review of the literature on medical marijuana since the Institute of Medicine report over a decade ago, with a trove of data that wasn't available to the IOM," said Rob Kampia, executive director of the Marijuana Policy Project. "It is simply incomprehensible that a medicine that is so clearly safe and effective remains banned from medical use by federal law and the laws of 37 states."


     The article, "Medicinal Use of Cannabis in the United States: Historical Perspectives, Current Trends, and Future Directions," is available at http://tinyurl.com/m9oo44. A complete list of the 33 U.S. clinical trials is available from Sunil Aggarwal at [email protected] or 206-375-3785.


     With more than 27,000 members and 100,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

Press Release: Seton Hall Center for Health & Pharm Law Supports NJ Medical Marijuana Act

FOR IMMEDIATE RELEASE: August 27, 2009 CONTACT: Ken @ (609) 394-2137 Seton Hall Center for Health & Pharm Law Supports NJ Medical Marijuana Act WHO: Seton Hall University School of Law Center for Health & Pharmaceutical Law & Policy WHAT: Published support for the “New Jersey Compassionate Use Medical Marijuana Act” WHEN: August 26, 2009 WHERE: A Position Paper in HEALTH REFORM WATCH available at: http://www.healthreformwatch.com/2009/08/26/position-paper-in-support-of-the-new-jersey-compassionate-use-medical-marijuana-act/ WHY: Because the legislation has been carefully drafted to allow New Jersey residents with debilitating medical conditions access to marijuana to ease their suffering without creating an undue risk of abuse or diversion. The Seton Hall University Center for Health & Pharmaceutical Law & Policy published a Position Paper today that supports the passage of the New Jersey Compassionate Use Medical Marijuana Act. The Center said that the legislation has been carefully drafted to allow New Jersey residents with debilitating medical conditions access to marijuana to ease their suffering without creating an undue risk of abuse or diversion. The Center cited available medical evidence that supports the use of marijuana to treat each of the debilitating medical conditions set forth in the Act: AIDS/HIV; cachexia (wasting syndrome); cancer; glaucoma; severe and persistent muscle spasms; severe nausea; severe or chronic pain; and seizures. The Center also addressed the issues of abuse and diversion. The Center noted that no state that has passed a medical marijuana law has subsequently experienced an increase in recreational marijuana use among its children and youth. The Act’s multiple safeguards against abuse and diversion of medical marijuana provide further reassurance, it noted. If passed, the Act would be among the most restrictive of all the states’ medical marijuana laws. Thirteen states, covering about 25% of the U.S. population, currently have medical marijuana programs. On February 23, the New Jersey Senate voted 22-16 to pass S119, the New Jersey Compassionate Use Medical Marijuana Act. The Assembly health committee voted 8-1 to pass an amended version of the bill on June 4. The bill must now pass the full Assembly. If the amended bill clears the Assembly, it would return to the Senate for a second vote because of the changes before it goes to Gov. Jon Corzine (D), who has said that he will sign the bill if it makes it to his desk. The mission of the Coalition for Medical Marijuana--New Jersey, a 501(c)(3) public charity, is to educate the public about the benefits of safe and legal access to medical marijuana. The Coalition is grateful for this well-researched and well-written Position Paper. For more info, contact: Ken Wolski, RN, MPA, Executive Director Coalition for Medical Marijuana--New Jersey, Inc. www.cmmnj.org 844 Spruce St., Trenton, NJ 08648 609.394.2137 [email protected]

Press Release: Study -- Marijuana May Protect Against Alcohol Brain Damage

FOR IMMEDIATE RELEASE   
AUGUST 21, 2009   

Study: Marijuana May Protect Against Alcohol Brain Damage

CONTACT: Bruce Mirken, MPP director of communications ............... 415-585-6404 or 202-215-4205

WASHINGTON, D.C. -- A study just published online by the journal Neurotoxicology and Teratology suggests that marijuana may protect the brain from some of the damage caused by binge drinking.

     The study, by researchers at the University of California San Diego, used a type of high-tech scan called diffusion tensor imaging to compare microscopic changes in brain white matter. The subjects were students aged 16-to-19, divided into three groups: binge drinkers (defined as having five or more drinks at one sitting for boys or four or more for girls), binge drinkers who also smoked marijuana, and a control group who had very little or no experience with either alcohol or drugs.

     As expected, the binge-drinking-only group showed evidence of white matter damage in eight regions examined, as demonstrated by lower fractional anisotropy (FA) scores. But in a finding the researchers describe as "unexpected," the binge-drinking/marijuana group had lower FA scores than the controls in only three of eight regions, and in seven regions the binge-drinking/marijuana group had higher scores -- indicating less damage -- than the binge drinkers who did not use marijuana.

     Brain white matter tracts were "more coherent in adolescents who binge drink and use marijuana than in adolescents who report only binge drinking," the researchers wrote. "It is possible that marijuana may have some neuroprotective properties in mitigating alcohol-related oxidative stress or excitotoxic cell death," as has already been shown in lab and animal studies.

     "This study suggests that not only is marijuana safer than alcohol, it may actually protect against some of the damage that booze causes," said Steve Fox, Marijuana Policy Project director of state campaigns and co-author of the new book, "Marijuana Is Safer: So Why Are We Driving People to Drink?" (which hit number 17 on the Amazon.com bestseller list). "It's far better for teens not to drink or smoke marijuana, but our nation's leaders send a dangerous message by defending laws that encourage the use of alcohol over marijuana."

     REFERENCE: Jacobus, J. et al. "White matter integrity in adolescents with histories of marijuana use and binge drinking." Neurotoxicology and Teratology.  http://dx.doi.org/10.1016/j.ntt.2009.07.006

     With more than 27,000 members and 100,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

Medical Marijuana: 10 years ago ...

Dear Friends:

Ten years ago yesterday, the National Academy of Sciences' Institute of Medicine (IOM) released its landmark report that forever changed the public debate on medical marijuana.

In November 1996, California became the first state to pass a medical marijuana ballot initiative. The following month, the Clinton administration struck back, threatening doctors if they recommended medical marijuana to patients. But the American Medical Association and the American public responded with outrage and condemnation, throwing the Clinton administration off-balance. The next month, in January 1997, the White House drug czar's office attempted to deflect attention by awarding $1 million in taxpayer money to the Institute of Medicine to conduct a two-year study of medical marijuana.

In 1997 and 1998, MPP brought dozens of patients to a series of IOM hearings to testify about their fear of being arrested. Indeed, many of the patients had already been arrested and/or incarcerated for using medical marijuana.

Then, on March 17, 1999, the Institute of Medicine finally released a report that was not at all what the drug czar's office had hoped for. The report contradicted the claims of the drug czar and other federals officials on a number of fronts:

1. It showed there is scientific evidence indicating that marijuana has medical uses.

2. It recommended that people with AIDS, cancer, and chronic pain who have an urgent need for marijuana be provided with immediate legal protection while further research is done on marijuana's medical uses.

3. It debunked the "gateway theory," saying that there is no evidence that using marijuana will "lead" someone to use cocaine and other drugs.

4. It said there is no evidence that allowing sick people to use medical marijuana will cause an increase in the recreational use of marijuana.

That report has been used as the intellectual foundation of most medical marijuana efforts in the decade since.


MPP co-founder Chuck Thomas with IOM investigators in 1998

The release of that report was the first time that MPP received a barrage of national media coverage, all over the course of just two weeks. But that media coverage pales in comparison to the coverage that MPP and the broader marijuana policy reform movement has been receiving over the last four months.

This is now a lesson in "be careful what you wish for." As the marijuana issue continues to explode across the political landscape in nearly all 50 states, MPP and our allies are getting stretched more and more thin ... as we attempt to capitalize on the opportunities that are presenting themselves in the news, in state legislatures, in Congress, and at the ballot box.

Anything you can give to help fund these exploding efforts would be greatly apprecated.

Thank you,
signature

Rob Kampia
Executive Director
Marijuana Policy Project
Washington, D.C.

P.S. As I've mentioned in previous alerts, a major philanthropist has committed to match the first $2.35 million that MPP can raise from the rest of the planet in 2009. This means that your donation today will be doubled.

Submissions Wanted: The 5th International Conference on the History of Drugs and Alcohol: The Pathways to Prohibition

The biannual conference of the Alcohol and Drugs in History Society is being hosted for the first time in the UK by the Centre for the Social History of Health and Healthcare, Glasgow, a research collaboration between the University of Strathclyde and Glasgow Caledonian University (www.gcal.ac.uk/historyofhealth). The conference is seeking papers and panels that connect with the broad subject of the 'pathways to prohibition'. Proposed papers or panels can be on any topic in the history of intoxicants, drugs and alcohol, and the conference hopes to draw on case studies from all periods and geographical contexts. Some issues to be considered include: 1) The representation of consumers which underlay decisions to instigate or reject prohibition 2) The strategies of consumers and suppliers when confronting the challenges of prohibition 3) Changing ideas about consumption under prohibition regimes 4) The relationship between local initiatives and the national and international politics of prohibition 5) Routes to, and out of, prohibition. Abstracts of proposed papers (no more than 500 words long) or of proposed panels should be sent by e-mail, fax or post by November 15th 2008 to: Dr Patricia Barton CSHHH Dept of History University of Strathclyde 16 Richmond Street Glasgow G1 1XQ UK E: [email protected] Tel: 44 (0)141 548 2932/ Fax: 44 (0)141 552 8509

Press Release: Horizons Presents Groundbreaking Research and Perspectives on Psychedelic Drugs in Medicine, Art, Spirituality and Culture at Conference September 19-21, at Judson Memorial Church

FOR IMMEDIATE RELEASE: September 15, 2008 CONTACT: Kevin Balktick at [email protected] or 646-537-1701, or Neal Goldsmith at [email protected] Horizons Presents Groundbreaking Research and Perspectives on Psychedelic Drugs in Medicine, Art, Spirituality and Culture at Conference September 19-21, at Judson Memorial Church Experts from across North America gather to discuss the ongoing renaissance in the exploration of psychedelic drugs. Presenters include medical researchers from several of North America's most prestigious universities, world-renown artists, religious scholars, bestselling authors and other key players. Horizons is the largest psychedelics conference in the Americas. Psychedelics are a unique class of psychoactive drugs that have been used by humans for thousands of years. Millions of people in every corner of the globe have used them to alter their consciousness in search of introspective contemplation, spiritual insights, creative exploration and physical and psychological healing. In the 1950s and early 1960s, legal research with psychedelics spurred important discoveries in neuroscience and psychology. During the 1960s, psychedelics entered worldwide popular culture. Questions about their safety, medical value, history and implications in politics and culture were unfortunately answered with numerous myths spread by both their recreational users and the media. The freewheeling sixties have become a distant memory and the hype of the millennial rave fever has faded as well. Now, a small group of dedicated researchers and activists has orchestrated a renaissance in psychedelic research that is re-shaping the public's understanding of these unique substances. Horizons brings together the brightest minds and boldest voices of this movement to share their research, insights and dreams for the future. Notable presenters include John Halpern MD from Harvard Medical School, Roland Griffiths Ph.D. From Johns Hopkins University School of Medicine, David E. Nichols MD from Purdue University, Isiah Saxon and Sean Hellfritsch, the video artists responsible for Bjork's most recent 3-D music video and pharmacological pioneers Alexander and Ann Shulgin. The venue, Judson Memorial Church, is a historically significant, landmarked location. It has a long history of promoting the arts, free speech and progressive politics. For more information please go to: www.horizonsnyc.org

Press Release: First Global Conference on Methamphetamine in Prague, Czech Republic, Sept. 15-16

FOR IMMEDIATE RELEASE For More Info: Luciano Colonna September 10, 2008 +00 (1) 801 635 7736 (USA); [email protected] FIRST GLOBAL CONFERENCE ON METHAMPHETAMINE TO ADDRESS 65 BILLION DOLLAR MARKET IN PRAGUE, CZECH REPUBLIC, SEPTEMBER 15-16, 2008 Experts >From 22 Nations Will Gather to Examine the Intersection between Methamphetamine, Public Health, Law Enforcement, and Civil Society. PRAGUE, Czech Republic, September 9 ­­­­-- While illicit production and use of synthetic drugs has stabilized in North America and Europe, it is on the rise in much of Asia and the Middle East, the United Nations Office on Drugs and Crime said Tuesday. The global market for amphetamine-type stimulants (ATS), worth an estimated 65 billion dollars in wholesale and retail sales combined, has stabilized or shown signs of decline in North America, Europe and Oceania but the problem has shifted to new markets over the past few years, the office said. According to Luciano Colonna, Chairman of the 2008 Global Conference on Methamphetamine, the use of ATS also continues to be used at an alarming rate in many parts of Eastern and Central Europe, the Russian Federation, and South Africa, with 36 million using ATS at least once on 2008. Colonna said that ATS are now more popular than heroin and cocaine combined. The First Global Conference on Methamphetamine will provide an arena for the world’s foremost scientists, leaders and professionals working on issues of drug use to come together to discuss a wide variety of topics centering on methamphetamine. The Conference will take place in Prague’s City Hall on Monday & Tuesday (September 15-16 2008). As the first event to gather global experts from a wide diversity of fields, the conference is assured to be an unparalleled event. Confirmed speakers from USA, China, Australia, Thailand, Russia, Canada, Mexico, South Africa, New Zealand, Indonesia, Malaysia, Israel, Poland, Iran, Slovakia Ukraine, Czech Republic, Great Britain and the United Nations will address the conference theme of “Science, Strategy and Response.” Representatives from international agencies, civil society, academia, science, law enforcement and others will have the unique opportunity to discuss key issues including: Treatment, HIV, Trafficking, Production, Environmental Impact, Law Enforcement, Policy, Current Research, Regional Updates, and Innovative Global Approaches. As nations struggle to develop appropriate responses to methamphetamine, it is crucial that the most current scientific research, information, and best practices be available to those seeking to implement solutions. The primary goal of the First Global Conference on Methamphetamine is to provide a context for this important work to take place. FOR MEDIA: A press conference will take place at the conference site at 10 AM, Monday (September 15, 2008. The major sessions of the conference are open to reporters. Site visits, photo opportunities and interviews can be arranged. For journalists not traveling to Prague, interviews and briefings with key spokespeople and presenters can be arranged on request. Sponsors and Partners include: The Czech Republic, Charles University, the City of Prague, Network Environmental Systems, Podane Ruce, Cranstoun Drug Services, Sananim, Institute Scan, Systems, Inc, and The Thorne Group. Website: www.globalmethamphetamine.com Contact: Luciano Colonna Chair, Executive Program Committee - 2008 Global Conference On Methamphetamine +00 (1) 801 635 7736 (USA); [email protected] Contact: Andy Lawson, Lawson Communications +420 775 035 757 (Europe); [email protected] ###

Press Release: Medical Student Section of AMA Unanimously Endorses Medical Marijuana

[Courtesy of Americans for Safe Access] For Immediate Release: June 14, 2008 Contact: ASA Media Liaison Kris Hermes at (510) 681-6361 or AMA-MSS member Sunil Aggarwal at (206) 375-3785 Medical Student Section of AMA Unanimously Endorses Medical Marijuana Resolution proceeds to AMA House of Delegates for a vote in November Chicago, IL -- The Medical Student Section (MSS) of the American Medical Association (AMA) unanimously approved a resolution yesterday urging the AMA to support the reclassification of marijuana for medical use. The AMA is currently holding its annual conference in Chicago and is making a number of policy decisions over the next few days. The MSS will send the resolution to the AMA House of Delegates for a final vote at its interim meeting in November. With nearly 50,000 members, the MSS is the largest and most influential organization of medical students in the United States. "While it is an historic occasion for any section of the AMA to endorse medical marijuana, the MSS is merely affirming existing science and urging the adoption of a sensible medical marijuana policy," said medical student and AMA-MSS member Sunil Aggarwal, who is leading the effort to seek AMA endorsement. "As a future medical doctor, I look forward to exploring and utilizing the many medical benefits of cannabinoid medicines in patient care." Aggarwal is also supported by many of his colleagues in the AMA already in the field of medicine. "This is a positive and necessary step in the right direction," said Dr. David Ostrow, a member of the AMA and Chair of the Medical & Scientific Advisory Board of Americans for Safe Access (ASA), the country's largest medical marijuana advocacy organization. "We are hopeful that the full house of delegates will follow the example set by the American College of Physicians earlier this year and vote to support this resolution, thereby placing the needs and safety of our patients above politics." The American College of Physicians (ACP) adopted a resolution in February, on which the AMA-MSS resolution is based. Like the AMA-MSS resolution, the ACP called for rescheduling of marijuana and an expansion of research into its medical efficacy. The ACP, at 124,000 members, is ranked as the country's second largest physician group and the largest organization of doctors of internal medicine. Since 1996, twelve U.S. states have adopted medical marijuana laws, and in 2002 a Times/CNN poll showed that 80% of Americans support access to physician-recommended medical marijuana.

Press Release: Study Confirms Medical Marijuana Pain Relief

[Courtesy of Marijuana Policy Project] 

FOR IMMEDIATE RELEASE: APRIL 17, 2008

Study Confirms Medical Marijuana Pain Relief
University of California Clinical Trial Shows Relief of Neuropathic Pain, Mild Side Effects

CONTACT: Bruce Mirken, MPP director of communications, 202-215-4205

DAVIS, CALIFORNIA -- A clinical trial conducted at the University of California at Davis and just published online by the Journal of Pain has demonstrated significant relief of neuropathic pain (pain caused by damage to nerves) stemming from a variety of causes. This is the second study in just over a year to show that marijuana relieves neuropathic pain, which is notoriously resistant to treatment with conventional pain drugs, including opioid narcotics. A UC San Francisco study published last year showed relief of HIV/AIDS-related neuropathy.


    In the new study, 38 patients experiencing neuropathic pain from diabetes, spinal injury, multiple sclerosis and other causes were given marijuana cigarettes of three different strengths: Zero percent THC (placebo), 3.5 percent THC or 7 percent THC. In each session, patients took the same number of puffs, following a standardized procedure to ensure uniformity of the dose received at each strength.


    Both doses of marijuana reduced pain significantly, producing marked declines in pain intensity that lasted over five hours. Researchers Barth Wilsey and colleagues wrote that side effects "were relatively inconsequential," and "psychoactive effects were minimal and well-tolerated." Although the scientists did express caution about the neurocognitive effects of the higher dose -- reflected in lower scores on some tests of memory and problem solving, the study was not designed to examine the potential for marijuana to allow reduced doses of narcotic painkillers that also cause cognitive impairment, a benefit widely reported by patients. For a copy of the complete study, contact MPP director of communications Bruce Mirken at 202-215-4205.


    "This is yet more proof that the American College of Physicians was right that U.S. government policy on medical marijuana is totally divorced from scientific reality," said Rob Kampia, executive director of the Marijuana Policy Project in Washington, D.C. "Congress needs to act to end the federal war on medical marijuana, but in the meantime states should act on their own to protect medical marijuana patients from arrest, as several states are considering right now."


    States where legislators are presently considering medical marijuana legislation include Illinois, New York and Minnesota. A medical marijuana initiative has qualified for Michigan's November ballot.


    With more than 23,000 members and 180,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

2008 Global Methamphetamine Conference -- Only One Week Left

2008 global conference on methamphetamine: science, strategy, and response        prague, september 15 – 16

<http://www.globalmethconference.com>

 

Abstract Submission Deadline ENDS April 22nd, 2008

 

Abstract Submission Guidelines

Topics and areas to be discussed include
 
Regional Updates  / Pharmacology / Enforcement Programs  / Clandestine Drug Cleanup / The Matrix Model of Treatment / Women and Methamphetamine / Latest Research /Health Consequences /  Policy  / Prosecution Issues / Trafficking / Toxicology / Innovative Interventions / Replacement Therapies / Prevention and Education / Hepatitis A, B, & C Virus / HIV Risk Behavior / Methamphetamine and Reproductive Health / Treatment / Youth and Use / Patterns of Use / Harm Reduction / innovative Interventions / Use Among MSM / Trafficking  / Community-based Coalitions / Injection Drug Use / Epidemiology



1) Individual proposals for presentations are welcome.
 
2) Presentation formats may include
 
Individual papers
    Reports on research-in-progress

    Round-table discussions

    Topic-centred workshops

    Or a format more appropriate to your own work.

- Please indicate your presentation format in your proposal.
- Please make sure that your proposal identifies the language you wish to present in.
 
3) Please send a 250-word proposal - along with a short bio - to the email address below.
 
- Your abstract should not contain more than 250 words
- No abstract will be accepted without a short bio.
 
Please send your abstract to [email protected]

The Deadline for abstract submissions is April 22, 2008
Speakers will be notified by May 2nd, 2008
 
Do you have a question or concern?

 Please feel free to contact me at [email protected]
--

Luciano Colonna
Chair
Executive Program Committee

2008 Global Conference on Methamphetamine
September 15 –16, 2008 - Prague, Czech Republic
www.globalmethconference.com

[email protected]
+00 (1) 801 635 7736 (USA mobile)
+44 (0) 208 987 6021 (London tell)
+44 (0) 208 994 1533 (London fax)
lucianocolonna (skype)

Subscribe to Academics